Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HepaStem in Acute on Chronic Liver Failure
NCT02946554Phase 2Completed
- Sponsor
- Cellaïon
- Start
- Dec 2016
- Primary completion
- Jul 2019
- Modality
- Mesenchymal Stem Cells
- Countries
- 2
01
Overview
A Phase 2 trial of hepastem in acute-on-chronic liver failure (ACLF), Cirrhosis, sponsored by Cellaïon. Started Dec 2016; status: completed.
02
Drugs
hepastem
03
Conditions
acute-on-chronic liver failure (ACLF)Cirrhosis
Beyond the preview
Go deeper on NCT02946554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02946554.